---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-008766"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:42:53.593341+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lipocine licenses TLANDO in Brazil; oral testosterone market grew 34% CAGR 2019-2023

## Summary
- Exclusive license and supply agreement with Aché Laboratórios for TLANDO in Brazil.
- Lipocine receives upfront payment, plus regulatory milestones and royalties on net sales.
- Aché is responsible for regulatory submission and approval in Brazil.
- No oral testosterone therapy is currently registered in Brazil; market CAGR 34% 2019-2023.
- TLANDO is FDA-approved for testosterone replacement therapy in adult males with hypogonadism.

## SEC filing metadata
- accession: 0001641172-25-008766
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000164117225008766/0001641172-25-008766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000164117225008766/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-008766
- JSON: https://secwatch.observer/filing/0001641172-25-008766.json
- Plain text: https://secwatch.observer/filing/0001641172-25-008766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.